@article{oai:niigata-u.repo.nii.ac.jp:00016300,
 author = {斎藤, 俊弘 and 片桐, 明善 and 冨田, 善彦},
 issue = {11},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Nov},
 note = {Metastatic renal cell cancer (RCC) is usually treated with immunotherapy using cytokines because it is a mostly chemoresistant malignancy. These therapies are generally based on interleukin-2 (IL-2) or interferon. However, their response rates were less than 20% and various side effects appeared. In order to improve response rate or reduce side effects, we have tried LAK (lymphokine-activated killer cells) therapy and low dose interferon γ therapy. LAK cells are peripheral blood lymphocytes activated in vitro by exposure to IL-2. LAK therapy was done 10 course for 9 patients in our hospital and the overall respones rate was 60%. On the other hand, low dose interferon γ therapy was done for 10 patients and the side effects were relatively small with the response rate of 10%. These results indicate that immunotherapy using cytokines are useful for metastatic renal cancer and its strategy, including dosage, combination therapy, is still to be investigated.},
 pages = {690--692},
 title = {6)腎細胞癌に対するサイトカイン治療（シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会）},
 volume = {112},
 year = {1998}
}